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ABSTRACT 
Kamra, Kajal, M.S. Department of Neuroscience, Cell Biology, and Physiology, Wright 
State University, 2019. Effect of Administration of Somatostatin Analogue on Blood 
Pressure in Chronic Intermittent Hypoxic Rats. 
           The cardiorespiratory system in our bodies does not adapt to Chronic Intermittent 
Hypoxia (CIH) and consequently syndromes such as sleep apnea lead to 
pathophysiological conditions like Hypertension. It has been demonstrated that the 
peripheral chemoreceptors underpin the development of these conditions and at present, 
there are no selective drug therapies for this form of hypertension. However, evidence 
suggests that peripheral chemoreflex sensitivity to CO2 & hypoxia is reduced by 
Somatostatin (SST) in humans. Our preliminary in-vitro studies have demonstrated that 
SST will blunt the response of the carotid body to hypoxia and decrease the baseline 
activity of the carotid body. We therefore hypothesize that SST analogues given in-vivo 
via osmotic minipumps will attenuate the increase in BP, thereby preventing systemic 
hypertension from developing during CIH.  
Adult male Sprague-Dawley rats were implanted with Osmotic minipumps containing 
sterile water or SST analogue (Octreotide Acetate) and then were exposed to CIH for ≤35 
days to induce hypertension. BPs were measured before, during and after IH conditioning. 
Each minipump administers the drug for only 28 days. It was predicted that the animals 
exposed to the SST analogue will be protected from CIH-induced hypertension. 
Data showed a sudden drop in BP post-surgery in all animals tested. This hypotension may 
have prevented the ability of chronic intermittent hypoxia to induce hypertension in both 
experimental and control animals. 
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Anatomy and Physiology 
 
          The carotid bodies (also known as glomus caroticum) are small peripheral sensory 
organs located at the bifurcation of the common carotid artery which respond primarily to 
changes in blood oxygen levels, blood carbon dioxide levels or pH (Wyatt, Evans and 
Peer’s review, 2010). The carotid bodies are also viewed as polymodal organ as they can 
respond to temperature and physiological fluctuations in extracellular potassium 
concentrations (Kumar, 2009) to produce cardio respiratory reflexes to restore blood gas 
homeostasis. The exact location of the carotid bodies is different among mammalian 
species and different individuals of the same species (Lopez-Barneo, Gonzalez, 2017) but 
is usually found at the bifurcation of the common carotid artery in the neck. The carotid 
body possesses of glomeruli / functional unit supplied with an extensive capillary network 
and connective tissue that separates glomus (T1) cells and sustentacular (T2) cells that are 
known to envelope type I cells (Lopez-Barneo, Gonzalez, 2017).  
          T1 (Glomus) cells are small (8-15 µm) ovoidal cells whereas, T2 (sustentacular) cells 
are elongated cell bodies (approximately 10 µm in diameter). Apart from their appearance, 
T1 and T2 cells can also be differentiated by abundance of mitochondria and presence of 
dense-core secretory vesicles in T1 cells (Lopez-Barneo, Gonzalez, 2017). The 
approximated ratio of T1:T2 cells is 4:1 (Donald et al., 1981). Other than T1 and T2 cells, 
CB of mammals also contain nestin⁺ cells that can produce fully grown glomus cells (Fig 
1B &D) (Ortega-Saenz et al., 2013). Under hypoxia, T2 cells, which are known to be 
inactive stem cells can get activated and result in formation of T1 cells or other cell types 
(Pardal R et al., 2007). 
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Figure 1. A) Schematic from Peers, Wyatt, & Evans (2010) showing the gross morphology 
and anatomical location of the carotid body at the bifurcation of the common carotid artery 
(CC). The CC diverges into the internal carotid (IC) and external carotid (EC); at the base 
of this bifurcation the carotid body is normally found. 
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Figure 2. Structure and organization of the carotid body (CB) adapted from Jose Lopez-
Barneo et al., 2016. A) Photograph of the human carotid bifurcation after cleaning the 
connective and fat tissue surrounding the CB (arrow) region. Scale bar, 1 cm. Male, 42 yr. 
old. B) Schematic representation of the cellular components in the CB glomerulus. v, Blood 
vessel. Nestin+ progenitor cells appear in green. C) Electron microscope photograph 
illustrating the ultrastructure and anatomical relations of the two main cellular elements in 
the mouse CB; type I cells (red) enveloped by type II cells (dark blue). The inset shows the 
abundance of mitochondria and dense core secretory vesicles in type I cells. D) 
Histological section of a human CB immunostained with antibodies against dopamine 
decarboxylase (DDC), a glomus cell marker, and against nestin, a progenitor cell marker. 
Scale bar 20 µm. 
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        In 1868, Pfluger announced that breathing is stimulated by hypoxia (Iturriaga, R., & 
Alcayaga, J. (2004)). In between 19th and 20th centuries, a structure similar to a “ganglion” 
(Iturriaga, R., & Alcayaga, J. (2004)) or “gland” (Nurse, C. A. (2010)) at bifurcation of 
common carotid artery was recognized by scientists but no physiological function was 
assigned to this organ until 1930. Heymans in 1930 recognized CB is a sensor of arterial 
hypoxia and was awarded with a Nobel prize for his contribution in this field. Verma et al., 
1975 provided evidence that CB sensory activity disappeared when T1 cells were cryo 
destroyed. This identified the T1 cells as the chemosensors. 
Neurotransmitters and their Release from Carotid Body Type I Cells 
 
          To counteract changes in blood gas or pH, T1 cells are activated and are depolarized 
by inhibition of K⁺ channels which results in voltage gated Ca2+ entry and the 
neurotransmitter release.  This then activates the afferent sensory nerve fibers of the CSN 
that along with CB T1 cells form a chemical synapse. Chemoreceptor information is then 
relayed to the respiratory center of brain stem to cause cardio respiratory and ventilatory 
reflexes restoring normal pH levels and blood gas levels in body (Ryan and Wyatt, 2018).  
CB T1 cells contain many neurotransmitters (mainly ACh, dopamine, ATP & Serotonin) 
of which ACh and ATP are likely to be accountable for activation of sensory nerve fibers 
(Fitzgerald et al., 1986; Zhang M et al., 2000) 
Sleep Apnea, Hypertension and Intermittent Hypoxia 
 
          Sleep apnea is a clinically prevalent disorder in which breathing repeatedly stops and 
starts every 15-30 seconds.  The main types of sleep apneas are Central Sleep Apnea 
(cessation of breathing of the respiratory rhythm) and Obstructive Sleep Apnea 
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(obstruction of the upper airway) (Nieto FJ et al., 2000; Young T et al., 1993.; Ramirez JM 
et al., 2013). The obstruction of the upper airway during sleep causes termination of air 
flow leading to intermittent hypoxia and affects an estimated 10 % of the population in the 
US (Nanduri, J. et al., 2017). 
           Patients suffering from SA can develop hypertension, myocardial ischemia, stroke 
and even unanticipated death (Hung et al., 1990). SA is a respiratory disease which can be 
caused by several factors. Apart from abnormal upper airway or defective central CO2 
chemoreceptors (Kumar, N. N. et al. 2015; Ramirez, J.-M. et al. 2013] it may also be caused 
due to abnormal CB activity (Orr, J. E., Malhotra, A., & Sands, S. A. (2017); Eckert, D. J., 
White, et al. 2013); Eckert, D. J., Malhotra, A., & Jordan, A. S. (2009)). 
         Peng et al., 2017 proposed that CB chemoreflex activity may result in both Central 
and Obstructive Sleep Apnea. They also suggested that increased CB chemoreflex begins 
with carotid sinus nerve activity (CSA) which then lead to OSA by lowering the muscle 
tone of the tongue which lead to blockage of the upper airway. 
       Patients with OSA get mainly treated with Continuous Positive Airway Pressure 
(CPAP) which is known to improve oxygenation (Peng et al., 2017) but is not significantly 
effective in some patients, while some find it difficult to tolerate (Peng et al., 2017).  An 
exaggerated CB chemosensory reflex in humans and rodents has been shown to contribute 
to IH-induced hypertension (Prabhakar et al., 2015). 
           By chronic ablation of CB or CSN that innervates the CB, chemosensory reflex gets 
disrupted, which prevents increased sympathetic nerve activity (SNA) as well as IH-
induced hypertension in rats exposed to CIH (Fletcher et al., 1992; Peng et al., 2014). 
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    Hypertension      
           “Population-based studies report an increased incidence of hypertension in OSA 
patients with strong correlation between the severity of apnea and hypertension.” 
(Nandhuri et al, 2017). 
          When exposed to IH, rodents have been shown to mimic the blood O2 saturation 
profiles during OSA and exhibit hypertension. (Fletcher, 1995; Kumar et al., 2006; Peng 
et al., 2006; Troncoso Brindeiro et al., 2007).  The level of O2 desaturation is parallel to 
elevation of systolic BP during SA which makes them hypertensive (Shephard et al., 1985). 
We know that intermittent hypoxia sensitizes the CB which increases SNA. A synergistic 
increase in SNA is seen when hypoxia and hypercapnia are the combined stimulus as seen 
in SA (Somers et al., 1988).   
          Considerable evidence suggests that cardiorespiratory systems can adjust to Chronic 
SH to enable to continue enough O2 delivery to tissues (Lahiri, S., Rozanov, C. & 
Cherniack, N.S (2000); Bisguard, G.E. (2000). On the other hand, chronic IH causes 
pathophysiological conditions like hypertension, myocardial infarcts and even stroke 
(Nieto, F.J. et al.2000; Shahar, E et al. (2001)). 
       Apart from exposure to repetitive episodic hypoxia or stress due to normal sleep 
disruption, there are various mechanisms that could contribute to chronic increase in BP in 
OSA – Changes in salt and fluid balance (Krieger et al., 1991, Warley et al., 1988) and 
fluctuations in intrathoracic pressure that modifies the heart and vascular system have also 
been held responsible for BP changes in OSA (Bromberger-Barnea et al., 1981). 
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 Evidence also suggests OSA as a self-sufficient hazard for systemic hypertension. It is 
known that OSA might lead to adverse cardiovascular consequences by increasing daytime 
and night time sympathoadrenal activity. Evidence shows elevated levels of urinary and 
catecholamine levels in OSA and increased muscle sympathetic nerve activity (SNA) 
during obstructive apnea. Hypertension of OSA is maintained even during wakefulness, 
thereby increasing risk of cardiovascular complications associated with hypertension (Sica 
et al., 2000). 
        Fletcher and his colleagues demonstrated that 35 days of episodic hypoxia mimicking 
the episodic hypoxemia of sleep apnea can cause a diurnal increase in mean blood pressure 
of 14 mmHg (Fletcher et al., 2017). The authors also reported that when rodents were 
exposed to episodic hypoxia, they exhibited an increase in Mean Arterial Blood Pressure 
(MAP). This increase was found to depend upon: 
a) Peripheral afferent inputs transversing the CSN  
b) Level of CO2 in the hypoxic gas mixture; i.e., eucapnic hypoxia  
c) An intact sympathetic NS (Fletcher et al.,1992).                                     
  Animals exposed to a similar experimental condition with a supply of room air for 30 
days instead of N2 showed change in MAP. 
         Fletcher and his colleagues did experiments focused on the roles of renal sympathetic 
nerve activity and the renin-angiotensin system in mediating the increased diurnal systemic 
hypertension in their model of IH (Fletcher et al., 2017). In their study, systemic 
hypertension was shown to be associated with activation of renin-angiotensin system as 
indicated by up-regulation of renin during the non-hypoxic periods of their protocol as well 
as the finding that blockade of the angiotensin II type I receptor eliminated the increase of 
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arterial blood pressure and renal nerve activity. These results provide substantial support 
for the role of the sympathetic system in the blood pressure response to long-term 
intermittent hypoxia (Fletcher et al., 1999). The key role of the sympathetic system was 
also supported by finding of A.L. Sica in anesthetized preparations that the amplitude of 
preganglionic SNA during hypoxia, hypercapnic, and asphyxic stimulation was 
significantly greater in animals previously exposed to CIH compared to control animals. 
The findings prove how chronic exposure to IH is linked with increase in activation of 
brain stem and some regions of neuro axis that are responsible in shaping the sympathetic 
outflow (Sica et al., 2000). 
         There is an increase in both SNA and minute ventilation from peripheral 
chemoreceptor stimulation in response to a hypoxic stress. It has also been shown that 
surgical removal of CB blocks sympathetic activation and prevents hypertension on IH 
subjected rats (Fletcher et al., 1992; Peng et al., 2003). 
Somatostatin and its Analogue, Octreotide Acetate 
 
        After the discovery of SST in 1973 (Brazeau et al., 1973), a new approach to the 
treatment of conditions associated with endocrine hypersecretion, such as acromegaly, 
Cushing’s disease, and symptoms of metastatic neuroendocrine tumors (NET), was 
initiated (Weckbecker et al., 2002). 
SST was first described in the hypothalamus but SST producing cells are also found in 
central and peripheral nervous system, pancreas, gut, thyroid, adrenal, spleen, liver, 
kidneys and prostate.  SST is also produced by immune cells. [Patel YC et al.,1999]. SST 
comes in 2 bioactive forms- SST 14 and SST 28 which are synthesized from 
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preprosomatostatin, a large precursor molecule SST is produced in different quantities by 
different cells and, at least in the rat, the gut accounts for 65% of total body SST-like 
immunoactivity, the brain for 25%, the pancreas for 5% and the remaining organs, for 5% 
[Patel YC et al.,1978].  SST is known to acts as a neurotransmitter and as an autocrine, 
paracrine or endocrine regulator. Numerous physiological functions including modulation 
of neurotransmission, cell secretion and proliferation, smooth muscle cell contractility, 
intestinal motility, absorption of nutrients and immune cell functions are controlled by SST 
(Patel YC et al., 1999). 
 
Effects of Somatostatin and the Acute Hypoxic Response 
 
          Somatostatin has been localized with in nerve fibers innervating the arterial 
chemoreceptors (Kummer et al., 1989, 1990 and Kameda 1989).  In a small pilot study 
where Somatostatin Acetate dissolved in saline to achieve a concentration of 0.05 mg/ml 
was infused into a forearm vein in human subjects at the rate of 10 ml/h and lasted 64 
minutes (Robbins et al., 1999).  Their breathing, heart rate and blood pressures were 
recorded throughout the experiment.  As a result, 5 out of 9 subjects reported side-affects 
like nausea, head ache and stomach-ache from SST administration.  No changes in heart 
rate or blood pressures were found but SST attenuated the fast (peripheral) component of 
the ventilatory response to hypercapnia under hypoxia but had no effects on the slow 
(central) component of the ventilatory response to hypercapnia.  It also depressed the 
ventilatory response to hypoxia (AVHR).   
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          In 1995, e Silva & Lewis showed that somatostatin also inhibited whole cell calcium 
current peaks by 24% recorded from chemoreceptor Type I cells from the rat carotid body. 
“In humans, infusions of somatostatin greatly reduce the ventilatory sensitivity to hypoxia 
(Maxwell et al., 1986 a, b; Filux et al., 1988). All this suggests that the most likely site of 
action of Somatostatin on the hypoxic ventilatory response is at the carotid body.” 
(Robbins et al., 1999). 
          Our collaborators, Dr. Richard Wilson and his students at University of Calgary, 
Canada carried out an in-vitro experiment where they took out rat carotid bodies still intact 
with the carotid sinus nerve (CSN) and perfused it with hypoxic perfusate.  They saw an 
increase in the firing frequency along the sinus nerve.  They then perfused it with SST     
(1µM) and saw a significant reduction in the baseline firing of the CSN activity.  Upon 
washing the SST away, the CSN activity was restored to the normal levels (Figure 3). 
(UNPUBLISHED WORK) 
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Figure 3. Effect of SST on carotid sinus nerve in-vitro (Unpublished data from Dr. Richard 
Wilson’s laboratory at University of Calgary, Canada): Upper figure- Y axis shows the 
change in CSN activity and the X axis shows the time in seconds. CSN activity increased 
when Carotid bodies (attached to CSN) were perfused with hypoxic perfusate (Hx) and the 
baseline CSN decreases when perfused with SST (1µM). The lower figure represents the 
mean data of this experiment in the form of bar graphs. 
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Table 1. Somatostatin and analogues: affinity for somatostatin receptors (Adapted from H. 
Reynaert et al., 2003). 
 
 
          SST and its analogues work through six G-Protein coupled receptors (SST1 through 
5) including two splice variants, SST 2A and SST 2B (Goodchild AK et al., 1982; Padley 
JR et al., 2003) that control the activity of ion channels (Ca2+, K+, Na+ and Cl-) and 
enzymes (Adenyl Cyclase, Phospholipase C, Phospholipase A2, Phosphoinositide 3-
Kinase and Guanylate Cyclase) culpable for the synthesis or degradation of intracellular 
second messenger (CAMP, inositol 1,4,5-triphosphate, diacylglycerol and CGMP). All the 
SSTRs are coupled negatively to adenylate cyclase, activate phosphotyrosine phosphates, 
and modulate MAP kinase, whereas subtype-specific actions are also evident (Goodchild 
AK et al., 1982; Padley JR et al., 2003). 
          There is evidence that SSTR and SST containing cell bodies and terminals are 
present in the ventral medulla where the respiratory centers are located (Peter G.R. Burke 
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et al., 2008). Not much is known about their functional roles, except that microinjection of 
SST evokes apnea (Peter G.R. Burke et al., 2008). 
          Peter G.R. Burke found that when SST is bilaterally injected at Rostral Ventrolateral 
Medulla (RVLM) pressor sites, it evokes bradycardia, a large depressor response and 
robust sympathoinhibition. They also found that activation of SST2A receptors in RVLM, 
located on only approximately 35% of pre-sympathetic neurons containing TH and/or PPe, 
evoked intense sympathetically mediated hypotension and bradycardia. 
         SST is known to attenuate cellular proliferation by a direct effect on cellular division 
(Payan D et al., 1984), by reduction of the release of both Growth hormone (GH) (Moreau 
et al., 1987) and Insulin Growth Factor (IGF) (Grant MB et al.,1994) and reduction of Ca2+ 
currents in neuron (Wang H et al., 1990). Tjen-A-Looi S in 1992 provided evidence that 
chronic infusion of SST-14 neurons (20ug/rat/h) reduces pulmonary arterial pressure in 
chronically hypoxic rats. 
          SST analogues are efficiently linked to the human SSTR selectivity profile, with a 
synergistic SSTR2 and SSTR5 binding appearing critical (Tolis et al., 2006). One such 
synthetic analogue of SST, Octreotide (an eight amino acid cyclic peptide analogue) has 
been in clinical trials since 1984. It has more protracted pharmacological actions than SST 
and primarily bind with high affinity to human SSTR2 but show reduced or no binding to 
SSTR 1, 3, 4 and 5 (Table 1) (Tolis et al., 2006). In many studies, Octreotide has been used 
to treat acromegaly and esophageal variceal hemorrhage in humans mainly as bolus 
injections of 50µg followed by 25-50µg/h (Reynaert et al., 2003). Some also use Long 
Acting Release (LAR) Octreotide by deep subcutaneous depot injections to administer a 
dose of 20mg-40mg/month (Colao et al., 2009; Tolis et al., 2006). 
18 
 
          Patients with acromegaly tend to develop hypertension due to multifactorial 
mechanisms. In a published study by George Toils and others in 2006, when treated with 
Octreotide for six months, there was a decrease in systolic blood pressure in patients with 
left ventricular hypertrophy.  
         “SST analogues (SSTA) have a beneficial effect on BP (G. Minniti et al., 2001; A. 
Coloa et al., 2001), significantly improve heart rate and cardiac function, reduce left 
ventricular mass, improve systolic and diastolic function, and exercise training (G. Minniti 
et al., 2001; A. Coloa et al., 2000; P. Maison et al., 2007), improve diastolic filling (L. De 
Marinis et al., 2008), and may even reduce the rate of arrythmias (A. Calao et al., 2012; 
G. Lombardi et al., 2002), without a significant influence over heart valve disease (A.A. 
van der Klaauw et al., 2006; A.A. van der Klaauw et al., 2008).” 
        In another study, eleven patients (seven females and four males) received Octreotide 
(100-200µg), three times daily, subcutaneously over a 6-month period. Overall, systolic 
and diastolic mean pressures, heart rate and electrocardiograms did not change 
significantly throughout the investigational period (Bartolomeo Merola et al., 1993). There 
is some evidence that SST can modify the renin-angiotensin system in a manner that could 
lower BP independent of any effect on the endocrine pancreas (Izumi Y et al., 1980). 
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Hypothesis and Summary 
          We hypothesized that SST analogues given in-vivo will attenuate systemic 
hypertension from developing during intermittent hypoxia by attenuating an increase in 
BP. 
         To test this hypothesis, we used 32 male Sprague Dawley rats – control rats (n=16) 
and experimental rats (n=16). The experimental rats were exposed to Chronic Intermittent 
Hypoxia (4-5% O2, 15 events/hour, 8 hours/day for ≤35 days) to induce hypertension. The 
control rats were exposed to room air throughout the experiment.   ALZET 2ml osmotic 
minipumps were surgically implanted subcutaneously to administer SST analogue, 
Octreotide Acetate in rats.  Blood pressure was recorded before and after the surgery and 
weekly thereafter by using CODA non-invasive BP system. 
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MATERIALS AND METHODS 
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Animals 
 
          38 adult male Sprague Dawley rats (170g) were used in this experiment (Envigo, 
Indianapolis, IN) They were randomly subcategorized into control (n=19) and 
experimental (n=19) groups. They were weighed separately at the time of arrival and each 
week thereafter. They were all fed standard rat chow (Teklad 8640 from Envigo) and water. 
Standardized Blood Pressures for Rats 
 
          From day 4 to day 5, i.e. after 3 days of rest and acclimation to the room, the rats 
were acclimated to the CODA non-invasive blood pressure system (a tail-cuff method, 
Kent Scientific Corporation) for 20 cycles per rat between 8:30 am to 11am only. On day 
6, the day before surgery, each animal was weighed, and baseline BPs were recorded using 
the CODA noninvasive BP system. BPs were also recorded two days after surgery (Post-
op BP) (day 9), on first (day 16), second (day 23), third (day 30) and fourth (day 37) week 
of exposure to CIH. 
          After placing the rats in the CODA rat holders/tubes (Figure 4) (made sure they were 
comfortable and not squished), the holders were placed on top of a dry paper towel on the 
warming platform/tray (to the desired temperature, 34⁰C). The O-cuff and VPR-cuff were 
gently placed up the tail until resistance was felt. A slight gap, not more than 2 mm was 
maintained between the two cuffs. These tail cuffs were attached to the CODA machine 
which was attached to a computer (Figure 5) where all the recordings were recorded. 
          For at least 10 minutes, the rats could get acclimated and the tail temperature to rise 
to 34⁰C. To achieve adequate tail temperatures quickly, a warm water filled glove was 
placed on the rat’s tail (avoiding tubing) and a warm pad (Kent Scientific) over the restraint 
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for rats. Water-glove and heating pad were placed and removed as necessary to maintain 
proper tail temperature.  
          Once the rats were calm & up to temperature, we ran the cycles. Each rat ran 1 time 
with a total of 5 acclimation and 15 regular cycles. The data was exported and saved by 
date, group and animal number onto a MS Excel spreadsheet for further statistics. No CIH 
exposure on the day of BP measurement was done. 
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Figure 4. A) Image of Rat Holders in-use. (Adapted from Kent Scientific Corporation 
Website- 
https://www.kentscientific.com/products/productView.asp?productID=6376&Mouse_Rat
=Holders&products=Nose+Cone+Animal+Holders+with+Stand) B) Image of warming 
pads used to keep the rat restrainers warm. (Adapted from Kent Scientific Corporation 
website- 
https://www.kentscientific.com/products/productView.asp?productID=6234&Mouse_Rat
=Warming+Pads&products=Far+Infrared+Warming+Pad) 
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A) 
 
B) 
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Figure 5. Schematic of Measurement of Blood Pressure using CODA non-invasive tail 
cuff method.  
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Figure 6. Schematic of experimental timeline used in this research project. Animals were 
acclimated to the experimental room for 3 days. On day 7, ALZET 2ml4 osmotic 
minipumps containing either DMSO or drug were surgically implanted subcutaneously in 
the back of the animals and blood pressure was recorded before and after the surgery and 
weekly thereafter for 4 weeks. 
 
 
 
 
 
 
  
28 
 
 
 
  
 
 
 
 
                                       
  
29 
 
Surgery 
 
          On day 7, we surgically implanted ALZET 2ml4 osmotic mini pumps (Model 2ML4; 
Alzet Corp., Palo Alto, CA) that were filled with 8.5µg/ml/Kg of Octreotide Acetate 
(Somatostatin Analogue from Fisher Scientific)/Sterilized Water for the experimental/ 
control animals respectively (The standard protocol uses 10µg/ml/Kg of Octreotide per rat 
(Schmid et al., 2012)). Each animal weighed different at the time of surgery, so different 
concentrations of drug were calculated accordingly. 
           On each experimental day, eight male Sprague Dawley rats (45-60 days old), one at 
a time, were exposed to 2-5% isoflurane and 100% oxygen at a flowrate of 0.5L/min in an 
anesthesia induction chamber. Once the animal was unconscious, it was transferred to a 
nose cone underneath a dissecting microscope where it was exposed to the same anesthetic 
gas and flow rate as in induction chamber. Reaching the proper anesthetic plane was 
ensured by testing the animals’ withdrawal reflex using a foot and tail pinch. Once the rat 
had no response to the pinch, its limbs were taped down to keep it stationary, and the pump 
implantation surgery was carried out. 
          Each implantation started with the shaving of the incision area with an electric razor 
and cleansing with 70% Ethanol; followed by scrubbing the area thrice with betadine using 
cotton applicators (Fisher Scientific) and cleansing with 2” x 2” cotton gauze pad (Fisher 
Scientific) and then again with 70% ethanol & gauze pad. 
          Using a surgical scalpel (World Precision Instruments, Scalpel Handle #3, German 
500236-G), a small mid-scapular incision was made along the vertebral column to expose 
subcutaneous fascia. Then by using a bigger surgical scissor and a needle holder (Fine 
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Science Tools, Crile-Wood, 12503-15), this initial incision was enlarged in order to make 
a pouch/pocket subcutaneously to hold the sterile osmotic mini pump.  The sterilized 
osmotic mini pump was then placed longitudinally (parallel to the spinal cord): flow 
moderator facing posteriorly (facing towards the tail) within the subcutaneous cavity. Any 
excessive bleeding was wiped off with a 2” x 2” gauze. To close the incision site, VISORB 
(absorbable) sutures were used (CP Medical, Coated Visorb, violet braided, Size: 4-0, 
Needle:C-3, Shape: 3/8 Circle). Starting with a surgeon’s knot on the posterior end of the 
incision and followed by continuous stitch on the way up to the top of the incision and then 
closing it up with another surgeon’s knot. The incision area was again lightly scrubbed 
with betadine to kill any bacteria or germs in that area to prevent infection. Immediately 
after the completion of each survival surgery, the rats were given a 0.1ml/100g dose of 
Carprofen as a pain reliever.  
 Working of ALZET 2ML4 Osmotic Mini Pump 
 
          Osmotic pump is made up of an outer semi permeable membrane, middle osmotic 
layer and an inner impermeable drug reservoir of 2 ml (2000 µl). The pump is designed to 
administer the drug at a pump rate of 2.5µl/h continuously for 28 days when filled and 
implanted. The fill volume of the pump reservoir should be over 90% of the mean fill 
volume (i.e. equal to 2000 µl) indicated in the lot specifications at the top of the instructions 
sheet in the ALZET 2ML4 osmotic mini pump box. 
         To avoid puncturing the pump reservoir, the filling needle provided with the pumps 
was only used. The pump was then capped with the flow moderator. 
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Once implanted, body fluid from the animal is taken up by the outermost semipermeable 
membrane, followed by the middle osmotic layer of the pump causing it to swell and thus 
shrinking the innermost reservoir volume and causing the drug to be delivered out of the 
pump into the animal’s body via flow moderator. 
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Figure 7. Schematic of ALZET osmotic minipump. 
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Exposure to Chronic Intermittent Hypoxia (CIH) 
 
          Freely mobile animals housed in a feeding cage (11 x 11.5 x 17 inch), two cages per 
session with up to four animals per cage were placed in hermetically sealed chronic 
intermittent hypoxic chambers (Figure 8) (15 x 20 x 21 inch; COY). With the help of gas 
mixer, the hypoxic chamber was flushed with 100% Nitrogen for 36 seconds to reduce the 
ambient fractional concentration of Oxygen (FIO2) to 5% for 1 sec. This was followed by 
infusion of Oxygen allowing FIO2 = 21%. In the meanwhile, when Nitrogen was being 
supplied to the hypoxic chamber, normoxic chamber was supplied with compressed air to 
simulate the same noise and air disturbance. The cycle was repeated 15 times/hour for 
8hours/day for ≤ 35 days. 
          This entire set of experiment was repeated with four different times, each time with 
a new set of animals (therefore, total N=32). Paired student’s T-Test was run for each group 
of animals and values ≤ 0.05 were considered statistically significant. Michael Bottomley, 
Statistical Programmer Analyst at Wright State University did a separate analysis for the 
data obtained through this experiment. For each of the three response variables (SBP, DBP 
and MAP), a repeated measures mixed effects ANOVA with a random effect for rat ID 
was run.  The repeated measures aspect takes the correlation between time points for each 
rat into effect and the random effect factors in the correlation for the 5 measurements on 
each rat at each of the time points.  A level of significance of alpha = 0.05 was used for 
each model. (See Appendix) 
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Figure 8. Experimental setup used to condition animals to Chronic Intermittent Hypoxia. 
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Figure 9. Chronic intermittent hypoxia system kinetics. T1: ramp down to hypoxia, T2: 
hypoxia soak, T3: ramp up to normoxia, T4: normoxia soak 
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Standardized Blood Pressures for Rats 
 
          This study is done to test the hypothesis that a sustained allocation of SST or SST 
analogue will attenuate BP in chronic intermittent hypoxic rats. Thirty-two male Sprague 
Dawley rats separated into two equal groups- Control (CNTRL) and Experimental (CIH) 
(n=18), were further divided into four equal sub-groups – Control + No Drug (CNTRL + 
DMSO), Control + Drug (CNTRL + SST), Experimental + No Drug (CIH + DMSO) and 
Experimental + Drug (CIH + SST).  After three to four days of acclimation to the room, 
baseline blood pressures (Systolic, Diastolic and Mean arterial) were measured one day 
before the surgery (PRE) and then on the third day after surgery (POST) and then weekly 
thereafter for up to four weeks (W1→ W4). 
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Figure 10 shows change in SBP from week 3 to week 4 in all 6 groups of animals. On Y 
axis is the systolic BP and on X axis are CNTRL + DMSO, CNTRL + SST, CIH + DMSO, 
CIH + SST, CNTRL group without surgery and CIH group without surgery. Error bars are 
the standard errors of the mean calculated as standard deviation/square root (n-1). A 
significant drop in SBP is seen from week 3 to week 4 in CNTRL + SST group, which 
opposes our hypothesis as this group was not expected to show any significant change in 
BP. A significant decrease (p≤0.05) (student’s t-test) in SBP is seen from week 3 to week 
4 in CIH + DMSO group of animals. This group also opposes our hypothesis. CIH + SST 
group of animals do not show a significant change in BP. This group was expected to show 
a significant decrease in BP at the end of week 4 and therefore failed our hypothesis. 
The last two groups depict results as expected on exposure to normoxia and CIH (but 
without surgery). A significant increase in BP is seen in animals that were exposed to CIH 
in comparison to animals that were not. This ensures that the CIH system works effectively. 
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Figure 10. Comparison of results of animals that did not undergo pump implantation 
(surgery) with animals that did undergo surgery for pump implantation. 
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Figure 11 shows the variability of the method measuring BP by tail cuff plethysmography. 
Y axis is the Systolic BP (mmHg) and on the X axis are 6 random animals from CNTRL + 
DMSO group. For each animal 5 SBP recordings are taken into consideration and 
variability with in each animal as well as between animals is depicted in the following 
figure. 
For animal 1, four out of five recordings fall in the range of 165mmHg -190mmHg. For 
animal 2, SBP recordings are in the range of 155mmHg-175mmHg. Animal 3 SBP is the 
range of 177mmHg-198mmHg. Animal 4 is in the range of 154mmHg-165mmHg. Animal 
5 is in the range of 190mmHg-215mmHg. Animal 6 shows most variation with in itself 
with 3 readings being in the range of 129mmHg-145mmHg and other two in the range of 
173mmHg-183mmHg. 
All these SBP ranges are higher than the normal SBP range which is 120-140mmHg. 
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Figure 11. Variability of tail-cuff BP measuring system with in animal and among other 
animals of CNTRL + DMSO group. 
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Figure 12 shows changes in SBP throughout the experimental timeline in CNTRL + SST 
(n=8), CNTRL + DMSO (n=8), CIH + SST (n=8) and CIH + DMSO (n=8) group of 
animals. Y axis is the SBP and on the X axis is different timepoints at which BP was 
measured- pre-surgery, post-surgery, week 1, week 2, week 3 and week 4. Error bars are 
the standard error of mean calculated as standard deviation/square root(n-1). 
For CNTRL + DMSO group, no significant difference (p>0.05) is seen from post-surgery 
to week 4 hence, supports our hypothesis. In CNTRL + SST group a significant increase is 
seen from post-surgery to Week 4 BP. In CIH + DMSO group, a significant increase (p≤
0.05) is seen from pre-surgery to post-surgery in systolic blood pressure, no significant 
change in BP is seen from pre-surgery to post-surgery BP for CIH + SST group of animals. 
A significant increase (p≤0.05) is seen from post-surgery to week 4 in DMSO containing 
CIH exposed group, but no significant difference is seen in case of drug containing CIH 
exposed group of animals. CIH + DMSO group of animals oppose our hypothesis. They 
should have had an increase in BP in comparison to CIH + SST group. CIH + SST also 
failed the hypothesis as it shows an increase in BP. All groups showed a drop in BP at week 
1. This could be because some other mechanism in the body tries to bring the BP to the 
normal range to maintain homeostasis.  
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Figure 12. Comparison of four groups of animals studied in this experiment showing that 
surgery/implantation of osmotic minipump causes a consistent, but transient, drop in BP. 
A) CNTRL + DMSO, B) CNTRL + SST, C) CIH + DMSO and D) CIH + SST 
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Figure 13 shows the predicted effects of DMSO in sham control group (n=4) on systolic, 
diastolic and mean arterial BP. Figure A shows systolic BP (mmHg) on Y axis and pre-
surgery BP, post-surgery BP, W1 BP, W2 BP, W3 BP and W4 BP on X axis. Same axis is 
followed for figure B Diastolic BP and figure C- MAP. Error bars are standard error of the 
mean calculated as standard deviation/ √(n). 
No changes in BP from pre-surgery to post-surgery in systolic, diastolic and MAP are 
expected.  Also, no significant difference in BP from post-surgery (baseline) to week 4.  
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Figure 13. Predicted effects of DMSO in sham control group BP. A) systolic BP, B) 
diastolic BP and C) mean arterial blood pressure. 
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Figure 14 shows the experimental effects of DMSO in sham control group (n=4) on 
systolic, diastolic and mean arterial BP. Figure A shows systolic BP (mmHg) on Y axis 
and pre-surgery BP, post-surgery BP, W1 BP, W2 BP, W3 BP and W4 BP on X axis. Same 
axis is followed for figure B Diastolic BP and figure C- MAP. Error bars are standard error 
of the mean calculated as standard deviation/ √(n). 
Systolic BP has a p>0.05 hence is not significant across the experimental timeline. A 
significant decrease (p≤0.05) in BP from pre-surgery to post-surgery is seen in MAP, but 
not in systolic and diastolic BP. No significant difference (p>0.05) in BP from post-surgery 
to week 4 in systolic, diastolic and MAP is seen. 
A drop in BP (systolic, diastolic and MAP) is seen at week 1. Systolic and diastolic BP 
recordings support our hypothesis as no final change in BP should be seen in control 
animals that were exposed to normoxia but MAP recordings oppose our hypothesis.  
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Figure 14. Experimental effects of DMSO in sham control group BP. A) systolic BP, B) 
diastolic BP and C) mean arterial blood pressure.  
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Figure 15 shows Predicted effects of DMSO on systolic (n=8) (figure 15A), diastolic (n=8) 
(figure 15B) and MAP (n=8) (figure 15C) recordings of sham control group and CIH 
exposed group of animals. Figure A shows systolic BP (mmHg) on Y axis and pre-surgery 
BP, post-surgery BP, W1 BP, W2 BP, W3 BP and W4 BP on X axis. Same axis is followed 
for figure B Diastolic BP and figure C- MAP. Error bars are standard error of the mean 
calculated as standard deviation/ √(n). 
 No significant difference is predicted from pre-surgery to post-surgery in systolic, diastolic 
and MAP for both sham control group and CIH exposed group.  Also, no significant 
difference is predicted in systolic, diastolic and MAP from post-surgery (baseline) to week 
4 for sham control group.  A significant increase (p≤0.001) from post-surgery to week 4 is 
predicted in systolic, diastolic and MAP for CIH exposed group of animals in comparison 
to the controls. 
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Figure 15. Predicted effects of DMSO in sham control group and CIH exposed group of 
animals’ BP. A) Systolic BP, B) Diastolic BP and C) MAP. 
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Figure 16 shows the experimental effects of DMSO in sham control group (n=4) and CIH 
exposed group of animals (n=4) on systolic, diastolic and MAP. Figure A shows systolic 
BP (mmHg) on Y axis and pre-surgery BP, post-surgery BP, W1 BP, W2 BP, W3 BP and 
W4 BP on X axis. Same axis is followed for figure B Diastolic BP and figure C- MAP. 
Error bars are standard error of the mean calculated as standard deviation/ √(n). 
No significant difference (p>0.05) is seen in systolic, diastolic and MAP for CIH exposed 
group over time. A significant decrease from post-surgery to week 4 in systolic, diastolic 
and MAP for CIH exposed group of animals is seen. 
CIH + DMSO group opposes our hypothesis. They should have had an increase in BP in 
comparison to CNTRL + DMSO group as they were exposed to CIH and not treated with 
SST. CNTRL + DMSO group (systolic and diastolic) support our hypothesis.  
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Figure 16. Experimental effects of DMSO in sham control group and CIH exposed group 
of animals’ BP. A) Systolic BP, B) Diastolic BP and C) MAP. 
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Figure 17 shows Predicted effects of DMSO (n=4) and drug (SST) (n=4) on systolic 
(n=8, ?̅? = 170.04 𝑣𝑠 174.3) (figure 17A), diastolic (n=8, ?̅? =133.33 vs 134.33) (figure 
17B) and MAP (n=8,  ?̅? =154.75 vs 154.75) (figure17C) in sham (normoxia) control group 
of animals.  Figure A shows systolic BP (mmHg) on Y axis and pre-surgery BP, post-
surgery BP, W1 BP, W2 BP, W3 BP and W4 BP on X axis. Same axis is followed for 
figure B Diastolic BP and figure C- MAP. Error bars are standard error of the mean 
calculated as standard deviation/ √(n). No significant difference (p>0.05) from pre-surgery 
to post-surgery or from post-surgery (baseline) to week for systolic, diastolic and MAP for 
both DMSO and drug containing sham control group. 
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Figure 17. Predicted effects of DMSO and drug (SST) in sham control group of animals. 
A) Systolic BP, B) Diastolic BP and C) MAP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
 
 
 
 
 
 
 
65 
 
Figure 18 shows the experimental effects of DMSO (n=4) and drug (SST) (n=4) on systolic 
(n=8), diastolic (n=8) and mean arterial blood pressure (n=8). Figure A shows systolic BP 
(mmHg) on Y axis and pre-surgery BP, post-surgery BP, W1 BP, W2 BP, W3 BP and W4 
BP on X axis. Same axis is followed for figure B Diastolic BP and figure C- MAP. Error 
bars are standard error of the mean calculated as standard deviation/ √(n). 
A significant increase (p≤0.05) is seen from pre-surgery to post-surgery in MAP for 
CNTRL + DMSO but none (p>0.05) is seen from pre-surgery to post-surgery for systolic, 
diastolic and MAP for drug containing sham control group. No significant difference seen 
from pre-surgery baseline to week 4 in systolic, diastolic and MAP for DMSO containing 
sham control group. No significant difference seen from post-surgery to week 4 in systolic, 
but a significant difference (p≤0.05) seen in diastolic and MAP for drug containing sham 
control group. CNTRL + DRUG group opposes our hypothesis. They were expected to not 
show any change in BP as they were exposed to normoxia. Whereas, CNTRL + DMSO 
(systolic and diastolic BP) support our hypothesis. 
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Figure 18. Experimental effects of DMSO and drug (SST) in sham control group of 
animals. A) Systolic BP, B) Diastolic BP and C) MAP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
 
 
 
 
 
 
 
 
68 
 
Figure 19 shows predicted effects of DMSO (n=4) and drug (SST) (n=4) on systolic 
(n=8, ?̅? =175.7 vs 178.36) (figure 17A), diastolic (n=8, ?̅? =135.73 vs 138.4) (figure 17B) 
and MAP (n=8, ?̅? =157.61 vs 162.28) (figure17C) in CIH exposed group of animals. 
Figure A shows systolic BP (mmHg) on Y axis and pre-surgery BP, post-surgery BP, W1 
BP, W2 BP, W3 BP and W4 BP on X axis. Same axis is followed for figure B Diastolic 
BP and figure C- MAP. Error bars are standard error of the mean calculated as standard 
deviation/ √(n). No significant difference (p>0.05) from pre-surgery to post-surgery in 
systolic, diastolic and MAP for both DMSO and drug containing CIH exposed groups.  A 
significant increase (p≤0.001) is predicted from post-surgery (baseline) to week 4 in 
systolic, diastolic and MAP for DMSO containing CIH exposed group.  No significant 
difference (p>0.05) from post-surgery (baseline) to week 4 in systolic, diastolic and MAP 
for drug containing CIH exposed group of animals. 
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Figure 19. Predicted effects of DMSO and drug (SST) in CIH exposed group of animals. 
A) Systolic BP, B) Diastolic BP and C) MAP. 
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Figure 20 shows the experimental effects of DMSO (n=4) and drug (SST) (n=4) in CIH 
exposed group of animals, both treated (with SST) and not treated (with DMSO) on 
systolic, diastolic and mean arterial blood pressure. Figure A shows systolic BP (mmHg) 
on Y axis and pre-surgery BP, post-surgery BP, W1 BP, W2 BP, W3 BP and W4 BP on X 
axis. Same axis is followed for figure B Diastolic BP and figure C- MAP. Error bars are 
standard error of the mean calculated as standard deviation/ √(n). 
A significant increase from pre-surgery to post-surgery in systolic (p≤0.01), diastolic 
(p≤0.001) and MAP (p≤0.001) for DMSO containing CIH exposed group is seen.  No 
significant difference (p>0.05) is seen from pre-surgery in systolic, diastolic and MAP seen 
for drug containing CIH exposed group of animals.  A significant decrease seen in systolic 
(p≤0.0001), diastolic (p≤0.01) and MAP (p≤0.01) from post-surgery (baseline) to week 4 
in DMSO containing CIH exposed group but no significant difference (p>0.05) seen in 
case of drug containing CIH exposed group of animals. 
CIH + DMSO group of animals oppose our hypothesis. They should have had an increase 
in BP in comparison to CIH + SST group. CIH + SST also failed the hypothesis as it 
showed a significant increase in BP. 
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Figure 20. Experimental effects of DMSO and drug (SST) in CIH exposed group of 
animals. A) Systolic BP, B) Diastolic BP and C) MAP. 
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The only rats to show a significant increase from W1 to W2 were the CIH rats on the SST, 
which is the opposite of the desired effect.  This group did show a descriptive decrease 
from W2 to W3 and from W3 to W4, although not a statistically significant decrease.  The 
control rats on the SST showed significant increases from Pre to W3, Post to W3, W1 to 
W3, and W2 to W3.  
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DISCUSSION 
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           Sleep apnea is a clinically prevalent disorder in which breathing repeatedly stops 
and starts every 15-30 seconds (Nieto FJ et al., 2000; Young T et al., 1993.; Ramirez JM 
et al., 2013). 
           The obstruction of the upper airway during sleep causes termination of air flow 
leading to intermittent hypoxia and affects an estimated 10 % of the population in the US 
(Nanduri et al., 2017). Patients suffering from SA showcase emanations involving 
hypertension, myocardial ischemia, stroke and even unanticipated death (Sica et al., 2000). 
Patients with OSA get mainly treated with CPAP which is known to improve oxygenation 
(Peng et al., 2017) but is not significantly effective in some patients, while some find it 
difficult to tolerate (Peng et al., 2017). An exaggerated CB chemosensory reflex in humans 
and rodents has been shown to contribute to IH-induced hypertension (Prabhakar et al., 
2015). 
          When exposed to IH, rodents have shown to mimic the blood O2 saturation profiles 
during OSA and exhibit hypertension (Fletcher et al., 1995; Kumar et al., 2006; Peng et 
al., 2006; Troncoso Brindeiro et al., 2007).  The level of O2 desaturation is parallel to 
elevation of systolic BP during SA (Shepard et al., 1985). 
        Based on all these findings and the findings by Dr. Wilson, we hypothesized that SST 
analogues given in-vitro will attenuate the response of carotid body to intermittent hypoxia 
and then prevent carotid body sensitization, thus preventing systemic hypertension from 
developing during intermittent hypoxia. 
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Important Findings 
 
CONTROL + DMSO: Since the animals were not exposed to CIH, they should not be 
hypertensive. Also, as they were not given any treatment drug (SST), we should see no 
change in BP from W1 to W4. Although, we might expect to see some changes in BP post-
surgery. 
       The observed drop in BP could be due to the use of anesthesia, hypovolemic shock, 
septic shock.  A rise in BP can be a result of pain or stress.  As per the actual data collected, 
interestingly, we see a significant drop in BP at W1 in all animals. In all animals that had 
surgery, all treated (Octreotide) and control groups, show a significant hypotension 
following surgery. We also see a significant drop in MAP in CONTROL + DMSO group 
of rats from Pre to Post (which could be due to septic shock) and an overall drop in BP 
from Pre-surgery to W4. The sudden drop in BP at W1 could have possibly not allowed 
the W4 BP to rise back to its normal BP levels. But we see no significant change in BP 
from post-surgery to W4 in Systolic, Diastolic and MAP. Fletcher et al., 1992 performed a 
similar experiment with almost same protocol and showed that the animals become 
hypertensive. BP was indirectly measured in unconscious rats using an inflatable tail-cuff 
and photoelectric sensor. It was different from our experiment as they did not perform any 
surgeries or implant minipumps. 
CIH + DMSO: Animals should become hypertensive which means their BP should 
increase.  Also, they were given the vehicle- DMSO, instead of the drug, SST, therefore 
we expected to see an increase in BP. Prabhakar et al., 2017 provided evidence that unlike 
ST (short term)-IH (10 days exposure to CIH), LT (long term)-IH (30 days) leads to 
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irreversible changes in elevated BP and irregular breathing and these are associated with 
persistent activation of the CB chemosensory reflex. 
       For this group of animals, we saw a significant increase in BP from pre-surgery to 
post-surgery which I speculate can be a result of pain or distress in animals due to surgery. 
A constant drop in BP at W1 is seen in this group of rats as well.  We also see a drop in BP 
from post-surgery to W4 which is exact opposite of what we expected. Surprisingly, from 
pre-surgery to W4, there is no significant difference in systolic, diastolic or MAP.  One 
could think that the CIH system may have been ineffective but that cannot be true. The 
effectiveness of the system was ensured when we performed CIH controls with no surgery 
before proceeding with the actual experiment. Figure 18 shows experimental results (n=6) 
for in-vivo studies of animals that did not undergo surgery. Here, we see a significant 
increase in systolic, diastolic and MAP of CIH control rats from W3 to W4.  
CONTROL + DRUG: This is the group of rats that were surgically implanted with pumps 
containing SST analogue but were not exposed to CIH. We expected them to not get 
hypertensive, therefore no increase in BP and therefore the drug should not work. They 
should behave like the controls with no drug. While analyzing the actual data, we saw that 
the drug had effects opposite to what we expected. There was a significant rise in BP from 
post-surgery to W4.  It should have been the opposite (Figure 15). MAP shows a significant 
change in pre and post-surgery baseline and no significant change from post-surgery to W4 
BP measurements. 
Final average group B [CNTRL + SST] (in gray) shows no significant change in BP from 
post-surgery to W4.  For diastolic and MAP, there is a significant change in BP from post-
surgery to W4.  
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       As the time frame of the experiment was limited by the lifespan of the pump. It is also 
strange that the control rats on SST showed significant increases from Pre to W3, Post to 
W3, W1 to W3 and W2 to W3. This group would have the least likely to show any increase 
in SBP of the three groups if the SST is effective. (see appendix). 
CIH + DRUG: We expect the animals to become hypertensive as they were exposed to 
CIH, which is why their BPs should increase since they were treated with drug-SST. 
Hoffman et al., 1989 demonstrated an increase in BP in animals with osmotic pumps 
containing SST analogues (dissolved in 0.9% saline) at a rate of 10µg/kg/h for 7 days in 
comparison to the controls with 0.9% NaCl in their pumps. 
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Systolic BP for adult male Sprague Dawley rats should be in the range of 120-130mmHg 
but our rats’ systolic BP was in the range of 160-170mmHg which means our rats were 
already hypertensive. They could have been hypertensive because of our approach to BP 
measurement. Non-invasive tail-cuff plethysmography is relatively less expensive and 
does not require any surgical implantations, but it also does not give precise results. 
Investigators have identified the technical factors that most likely affect the accuracy of 
tail-cuff measurements while simultaneously recording BP using telemetry. These include 
entry of the investigator into the room where the measurements were performed, moving 
the cages around, handling the rodent, restraint of the rodent and inflation of the cuff on 
the tail. Changes in the BP and heart rate induced by restraint stress and tail-cuff inflation 
did not diminish in magnitude, even after many repeated trials. Telemetry on the other hand 
is the “gold standard” of BP measurement (Gregory D. Fink, Editorial, AHA, ASA). 
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Future experiments 
 
       The unexpected drop in BP post-surgery may have prevented the rise of BP in CIH + 
SST animals and to avoid any discrepancies in the results, any surgical implantations prior 
to BP recordings should be avoided and alternative ways of drug delivery should be 
considered. Use of depot injections to avoid unnecessary fluctuations in BP could be used. 
Also, the use of CODA non-invasive tail cuff BP measurement system was not the best 
choice. Fletcher and his colleagues observed an increase in MAP in rodents exposed to 
CIH for 7 h/day for 35 days during their diurnal sleep (Fletcher et al., 1992b)). They placed 
indwelling arterial catheter to measure BP. Next time, a greater number of animals and the 
use of telemetry for BP recordings can give us better and more accurate results. 
Potential Pitfalls 
       In many studies, Octreotide has been used to treat acromegaly and esophageal variceal 
hemorrhage in humans mainly as bolus injections of 50µg followed by 25-50µg/h 
(Reynaert et al., 2003). Some also use Long Acting Release (LAR) Octreotide by deep 
subcutaneous depot injections to administer a dose of 20mg-40mg/month (Colao et al., 
2009; Tolis et al., 2006). However, to study Long-Term (LT) effects of SST or SSTA, a 
dose of 10µg/kg/h or 8mg/kg/month is considered a standard protocol (Schmid et al., 
2012). In the current project, we intended to use 10µg/kg/h of SSTA concentration but due 
to wrong calculations we ended up using 8.5µg/kg/h. 
With a smaller size in comparison to humans, the basal metabolic rate- the rate of energy 
production over a fixed period of time under constant conditions- is much less than that of 
man, because of less body mass. However, the mass-specific rate, that is, the basal 
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metabolic rate per gram of body weight is known to be seven times greater in rodents than 
in humans (Lloyd et al., 2005). As a consequence, it is likely that rats will metabolize 
Octreotide drug faster than humans. 
Increasing the dose of Octreotide should help mitigate the problems caused by high 
metabolic rate and increased rate of drug metabolism. Three conventional concentrations 
of drug- 10µg/Kg/h, 30µg/Kg/h and 100µg/Kg/h could be used. 
The subtype of SSTRs on the carotid body and carotid sinus nerve are not known but we 
do know that the SST analogue Octreotide has high affinity for SSTR2 and SSTR5 and 
some affinity for SSTR3 (See Table 1). There is a possibility that the CB/CSN may not 
have any SSTR 2, 3 and 5 which means Octreotide would never work. To avoid this, other 
SST analogues such as Vapreotide or Somatuline could be tested. They have affinities for 
SSTR 2 through 5. 
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                                                                                            Michael Bottomley 
                                                                          Statistical Programmer Analyst 
                                                                      Statistical Consulting Center 
                                                                 3640 Colonel Glenn Hwy, 130 M&M 
                                                                                                       Dayton, OH 45435-0001 
                                                                          P: 937-775-2286     F: 937-775-2081 
                                                                                 E: michael.bottomley@wright.edu 
 
 
DATE: 13 February 2018 
TO: Kamra, Kajal 
FROM: Mike Bottomley 
SUBJECT: Final Report for CIH Analysis 
 
Dear Kajal, 
 
Here are the results of the analysis for your chronic intermittent hypoxia (CIH) data.  You 
are interested in determining if a drug (SST) has any effect on various blood pressure 
measures of rats undergoing CIH.   You have four treatment groups:  
(i) Normal oxygen conditions and placebo 
(ii) Normal oxygen conditions and SST 
(iii) CIH and placebo 
(iv) CIH and SST 
To simulate CIH the rats were placed in a chamber that was intermittently flooded with 
nitrogen to lower the oxygen content, and shortly thereafter, the oxygen content was 
returned to a regular level.  Rats on the drug and rats not on the drug were present in all 
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cages.  The cages that were not exposed to the CIH conditions had a device that mimics 
the sound of the nitrogen blast in order to keep the conditions as similar as possible.   
You recorded the systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean 
arterial pressure (MAP) of the rats.  The rats were measured at the start of the experiment, 
after a pump was surgically implanted, and then once a week for four weeks.  Five 
measurements were taken at each time point.  Due to complications arising from the 
surgery that implanted the pumps, some of the rats had to be removed from the experiment 
before the end of the study. Rats that were removed within a week after the surgery were 
excluded from the analysis since the drug would not have had ample time to show an effect.  
For each of the three response variables a repeated measures mixed effects ANOVA with 
a random effect for rat ID was run.  The repeated measures aspect takes the correlation 
between time points for each rat into effect and the random effect factors in the correlation 
for the 5 measurements on each rat at each of the time points.  A level of significance of 
alpha = 0.05 was used for each model.  Post hoc pairwise comparisons were made via 
Tukey’s multiple comparison procedure, which controls for an inflated type I error rate 
(rejecting the null hypothesis of no difference when in reality there actually is no 
difference) that can arise when multiple comparisons are made.  This procedure guarantees 
that the experiment-wise type I error rate for each of the three models is at most alpha = 
0.05. All analyses were performed on SAS version 9.4.  Descriptive statistics for each of 
the variables at each time point for each of the treatment groups are given below in Table 
1. 
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Group Time 
No. of  
Obs Variable Label N Mean Std Dev Minimum Maximum 
N 
Miss 
CNTRL + 
DMSO 
Pre 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
5 
3
5 
3
5 
169.1
1 
129.1
1 
149.2
9 
23.79 
22.28 
28.26 
107.00 
80.00 
89.00 
210.00 
175.00 
210.00 
0 
0 
0 
Post 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
5 
3
5 
3
5 
170.8
9 
132.6
0 
144.9
4 
21.38 
19.86 
19.02 
134.00 
108.00 
120.00 
217.00 
180.00 
189.00 
0 
0 
0 
W1 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
5 
3
5 
3
5 
148.1
1 
110.1
7 
122.4
6 
33.21 
26.66 
28.16 
95.00 
73.00 
84.00 
203.00 
163.00 
176.00 
0 
0 
0 
W2 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
5 
3
5 
3
5 
161.4
9 
121.2
3 
138.4
6 
20.55 
19.49 
22.59 
135.00 
91.00 
108.00 
214.00 
177.00 
187.00 
0 
0 
0 
W3 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
0 
3
0 
3
0 
170.8
3 
134.0
3 
145.8
7 
25.40 
25.56 
25.07 
131.00 
90.00 
105.00 
218.00 
192.00 
200.00 
5 
5 
5 
W4 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
0 
3
0 
3
0 
170.8
7 
131.3
7 
144.2
7 
24.07 
21.55 
20.64 
117.00 
74.00 
96.00 
218.00 
174.00 
188.00 
5 
5 
5 
CIH + 
DMSO 
Pre 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
5 
3
5 
3
5 
151.4
9 
113.4
3 
125.7
7 
28.81 
21.03 
23.18 
96.00 
79.00 
84.00 
201.00 
154.00 
166.00 
0 
0 
0 
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Group Time 
No. of  
Obs Variable Label N Mean Std Dev Minimum Maximum 
N 
Miss 
Post 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
5 
3
5 
3
5 
156.0
9 
119.4
9 
131.3
7 
27.40 
34.24 
30.93 
106.00 
56.00 
73.00 
204.00 
194.00 
197.00 
0 
0 
0 
W1 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
5 
3
5 
3
5 
141.0
3 
105.6
3 
117.0
3 
37.53 
24.33 
28.17 
70.00 
53.00 
58.00 
191.00 
149.00 
163.00 
0 
0 
0 
W2 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
5 
3
5 
3
5 
160.8
9 
119.3
7 
132.8
3 
27.34 
19.34 
21.27 
114.00 
86.00 
96.00 
218.00 
154.00 
164.00 
0 
0 
0 
W3 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
5 
3
5 
3
5 
156.3
1 
119.0
6 
131.1
7 
33.68 
24.52 
27.05 
99.00 
75.00 
85.00 
231.00 
161.00 
184.00 
0 
0 
0 
W4 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
2
5 
2
5 
2
5 
139.6
4 
110.4
8 
119.9
2 
27.61 
19.40 
21.51 
84.00 
74.00 
77.00 
178.00 
140.00 
152.00 
10 
10 
10 
CNTRL + 
DRUG 
Pre 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
5 
3
5 
3
5 
142.6
3 
106.4
0 
118.1
7 
33.25 
25.13 
27.63 
94.00 
69.00 
79.00 
197.00 
147.00 
160.00 
0 
0 
0 
Post 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
5 
3
5 
3
5 
147.0
6 
109.0
9 
121.3
4 
38.69 
27.20 
30.25 
37.00 
32.00 
33.00 
211.00 
170.00 
183.00 
0 
0 
0 
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Group Time 
No. of  
Obs Variable Label N Mean Std Dev Minimum Maximum 
N 
Miss 
W1 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
5 
3
5 
3
5 
145.6
3 
109.9
4 
121.4
6 
31.04 
24.35 
25.85 
87.00 
66.00 
74.00 
203.00 
180.00 
187.00 
0 
0 
0 
W2 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
5 
3
5 
3
5 
150.8
0 
115.2
3 
126.6
9 
29.80 
25.89 
26.27 
89.00 
53.00 
79.00 
194.00 
166.00 
174.00 
0 
0 
0 
W3 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
5 
3
5 
3
5 
176.3
4 
136.0
0 
149.2
0 
22.69 
21.77 
19.88 
137.00 
100.00 
117.00 
222.00 
195.00 
202.00 
0 
0 
0 
W4 35 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
3
5 
3
5 
3
5 
156.6
6 
122.9
4 
133.8
3 
43.95 
37.20 
38.96 
82.00 
61.00 
68.00 
230.00 
181.00 
197.00 
0 
0 
0 
CIH + 
DRUG 
Pre 25 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
2
5 
2
5 
2
5 
157.6
0 
121.1
6 
133.4
0 
27.04 
27.57 
26.94 
106.00 
67.00 
80.00 
194.00 
162.00 
170.00 
0 
0 
0 
Post 25 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
2
5 
2
5 
2
5 
162.6
8 
126.6
0 
138.3
2 
23.31 
26.43 
24.76 
116.00 
89.00 
98.00 
204.00 
194.00 
197.00 
0 
0 
0 
W1 25 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
2
5 
2
5 
2
5 
148.8
0 
108.6
0 
121.6
4 
32.83 
29.36 
29.75 
104.00 
78.00 
86.00 
237.00 
189.00 
197.00 
0 
0 
0 
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Group Time 
No. of  
Obs Variable Label N Mean Std Dev Minimum Maximum 
N 
Miss 
W2 25 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
2
5 
2
5 
2
5 
178.2
4 
137.1
2 
150.5
6 
24.48 
18.41 
18.71 
136.00 
112.00 
120.00 
236.00 
188.00 
193.00 
0 
0 
0 
W3 25 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
2
5 
2
5 
2
5 
165.9
6 
131.1
6 
142.1
2 
23.15 
18.63 
19.00 
129.00 
100.00 
109.00 
217.00 
174.00 
183.00 
0 
0 
0 
W4 25 SBP 
DBP 
MAP 
SBP 
DBP 
MAP 
2
5 
2
5 
2
5 
156.2
8 
124.0
8 
134.4
0 
29.38 
27.29 
26.88 
90.00 
57.00 
69.00 
204.00 
169.00 
178.00 
0 
0 
0 
 
Table 1: Descriptive statistics for CIH SST data by treatment group and time 
 
The following three sections detail the results for each of the three response variables.  In 
each of the three models, presence of a significant interaction between treatment group and 
time was detected (P < 0.0001 for each model).  This is evidence that any potential 
treatment effects are not constant across time.  As a result, the time points had to be 
compared individually.  This resulted in 276 pairwise comparisons being made for each of 
the three models that were run.  Using a level of alpha = 0.05, with 276 comparisons you 
would expect to commit around 14 type I errors by chance, which is why I chose to use 
Tukey’s multiple comparison procedure.  The interaction is evidenced in the interaction 
plots (Figures 1-3) by the non-parallel lines.  If the treatment effect were constant across 
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all time points the lines would be approximately parallel and the interaction term would 
not be statistically significant.  
I. Systolic Blood Pressure 
Of the 276 pairwise comparisons, those that had significant adjusted P-values are given 
below in Table 2.  Positive estimated mean differences indicate the first value was higher, 
negative estimated mean differences indicate the second value was higher.  The adjusted 
95% confidence intervals give a range of plausible values for the true mean difference.  
These intervals appear somewhat wide.  This is likely due to the adjustment made to correct 
for the multiple comparisons, as well as having a relatively small sample size that displayed 
a high amount of variance.  The order of subtraction is the same as the order of listing in 
the “Comparison” column.  The interaction plot follows in Figure 1. 
 
 
 Comparison  Estimated Mean 
Difference 
Adjusted 95% 
Confidence Interval 
Adjusted P-value 
CIH + DRUG W1        
- CIH + DRUG W2 
-29.44 (-56.99, -1.89) 0.0211 
CNTRL + DMSO 
Post - CNTRL + 
DMSO W1 
22.77 (1.75, 43.80) 0.0174 
CNTRL + DRUG 
Post - CNTRL + 
DRUG W3 
-29.29 (-50.66, -7.91) 0.0002 
CNTRL + DRUG 
Pre   - CNTRL + 
DRUG W3 
-33.71 (-55.15, -12.28) < 0.0001 
CNTRL + DRUG 
W1  - CNTRL + 
DRUG W3 
-30.71 (-51.74, -9.69) < 0.0001 
CNTRL + DRUG 
W2  - CNTRL + 
DRUG W3 
-25.54 (-48.83, -2.26) 0.0144 
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Table 2: All significant pairwise comparisons for SBP 
 
Figure 1: Interaction plot for SBP 
 
As we discussed at one of our meetings, some of these results are rather curious.  
Descriptively, all of the rats displayed a decrease from Post to W1 (whether or not it was a 
statistically significant decrease), which is to be expected while they recover from the 
surgery.  However, the only rats to show a significant increase from W1 to W2 were the 
CIH rats on the SST, which is the opposite of the desired effect.  However, it could be 
possible that the SST takes time to start working (based on your decision to exclude rats 
who were removed before W2.  This group did show a descriptive decrease from W2 to 
SBP
         130
         140
         150
         160
         170
         180
Time
Pre Post W1 W2 W3 W4
Means by Group and Time
Group CNTRL + DMSO CIH + DMSO CNTRL + DRUG CIH + DRUG
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W3 and from W3 to W4, although not a statistically significant decrease.  Perhaps with a 
larger sample size and fewer pairwise comparisons this would become statistically 
significant.  It is also possible that the drug did not have ample time to take full effect and 
given more time, this downward trend might have continued (note that this is pure 
speculation).  I think you mentioned the timeframe of the experiment was limited by the 
lifespan of the pump. It is also strange that the control rats on the SST showed significant 
increases from Pre to W3, Post to W3, W1 to W3, and W2 to W3.  It would seem that this 
group would have been the least likely to show any increase in SBP of the three groups if 
the SST is effective.   
 
II. Diastolic Blood Pressure 
 
Comparison  Estimated Mean 
Difference 
Adjusted 95% 
Confidence Interval 
Adjusted P-value 
CIH + DRUG W1        
- CIH + DRUG W2 
-28.52 (-50.80, -6.24) 0.0010 
CIH + DRUG W1        
- CIH + DRUG W3 
-22.56 (-44.32, -0.80) 0.0321 
CNTRL + DMSO 
Post - CNTRL + 
DMSO W1 
22.43 (1.22, 43.64) 0.0247 
CNTRL + DMSO 
W1  - CNTRL + 
DMSO W3 
-20.71 (-39.97, -1.45) 0.0196 
CNTRL + DRUG 
Post - CNTRL + 
DRUG W3 
-26.91 (-48.88, -4.95) 0.0023 
CNTRL + DRUG Pre   
- CNTRL + DRUG 
W3 
-29.60 (-47.63, -11.57) < 0.001 
CNTRL + DRUG W1  
- CNTRL + DRUG 
W3 
-26.06 (-44.45, -7.66) <0.0001 
CNTRL + DRUG W2  
- CNTRL + DRUG 
W3 
-20.77 (-37.05, -4.49) 0.0010 
Table 3: All significant pairwise comparisons for DBP 
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Figure 2: Interaction plot for DBP 
 
All significant pairwise comparisons for SBP were also significant for DBP.  Two 
additional pairwise comparisons were also significant.  CIH rats on SST had a significantly 
higher mean DBP at W3 compared to W1.  Control oxygen rats on the placebo had a 
significantly higher mean DBP at W3 compared to W1. 
 
 
 
 
DBP
         100
         110
         120
         130
         140
Time
Pre Post W1 W2 W3 W4
Means by Group and Time
Group CNTRL + DMSO CIH + DMSO CNTRL + DRUG CIH + DRUG
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III. Mean Arterial Pressure 
 
Comparison  Estimated Mean 
Difference 
Adjusted 95% 
Confidence Interval 
Adjusted P-value 
CIH + DRUG W1        
- CIH + DRUG W2 
-28.92 (-52.18, -5.66) 0.0017 
CNTRL + DMSO 
Post - CNTRL + 
DMSO W1 
22.49 (1.20, 43.77) 0.0250 
CNTRL + DMSO 
Pre  - CNTRL + 
DMSO W1 
26.83 (5.72, 47.94) 0.0011 
CNTRL + DRUG 
Post - CNTRL + 
DRUG W3 
-27.86 (-50.43, -5.29) 0.0020 
CNTRL + DRUG 
Pre   - CNTRL + 
DRUG W3 
-31.03 (-50.96, -11.10) < 0.0001 
CNTRL + DRUG 
W1  - CNTRL + 
DRUG W3 
-27.74 (-46.35, -9.14) < 0.0001 
CNTRL + DRUG 
W2  - CNTRL + 
DRUG W3 
-22.51 (-39.00, -6.03) 0.0002 
Table 4: All significant pairwise comparisons for MAP 
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Figure 3: Interaction plot for MAP 
 
MAP shared many of the same pairwise comparisons as SBP and DBP.  One that was 
different was the mean MAP was significantly higher Pre compared to W1 for the control 
oxygen plus placebo group.   
Let me know if you have any questions about anything contained in this report. 
 
Sincerely, 
Mike Bottomley 
MAP
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         120
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         140
         150
         160
Time
Pre Post W1 W2 W3 W4
Means by Group and Time
Group CNTRL + DMSO CIH + DMSO CNTRL + DRUG CIH + DRUG
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